February 3, 2021 09:12 AM EST

Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug

Nicole DeFeudis

Editor

After turning around Celgene’s S1P modulator for a long-awaited approval in multiple sclerosis, Bristol Myers Squibb is now trading in an FDA wildcard to get …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Bris­tol My­ers Squibb turns in pri­or­i­ty re­view vouch­er for sup­ple­men­tal in­di­ca­tion on an old Cel­gene drug

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug